|
PL220952B1
(pl)
|
2002-01-22 |
2016-01-29 |
Warner Lambert Co |
2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
|
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
CA2624965A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of pi3k.alpha.
|
|
GEP20115304B
(en)
*
|
2005-10-07 |
2011-10-10 |
Exelixis Inc |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
|
|
EP2069344A2
(en)
*
|
2006-09-08 |
2009-06-17 |
Pfizer Products Inc. |
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
|
ES2366489T3
(es)
|
2006-09-15 |
2011-10-20 |
Pfizer Products Inc. |
Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
US20080182853A1
(en)
*
|
2006-12-14 |
2008-07-31 |
Inna Kruman |
Methods of neuroprotection by cyclin-dependent kinase inhibition
|
|
US9259399B2
(en)
*
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
NZ586069A
(en)
|
2007-12-19 |
2012-05-25 |
Amgen Inc |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
ATE531372T1
(de)
*
|
2008-04-07 |
2011-11-15 |
Amgen Inc |
Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
|
|
CA2738909A1
(en)
*
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
EP2341911A4
(en)
*
|
2008-10-01 |
2012-10-24 |
Univ North Carolina |
HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
AU2010232670B2
(en)
|
2009-04-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
|
|
ES2561216T3
(es)
|
2009-05-13 |
2016-02-25 |
The University Of North Carolina At Chapel Hill |
Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
|
|
ES2633317T3
(es)
|
2009-11-06 |
2017-09-20 |
Plexxikon, Inc. |
Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
|
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
|
TWI510487B
(zh)
|
2010-04-21 |
2015-12-01 |
Plexxikon Inc |
用於激酶調節的化合物和方法及其適應症
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
EP2640394A4
(en)
*
|
2010-11-17 |
2015-02-25 |
Univ North Carolina |
PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
CN103517710B
(zh)
|
2011-02-07 |
2017-05-31 |
普莱希科公司 |
用于激酶调节的化合物
|
|
ES2620521T3
(es)
|
2011-03-23 |
2017-06-28 |
Amgen Inc. |
Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
|
|
ES2702487T3
(es)
|
2011-06-17 |
2019-03-01 |
Nantenergy Inc |
Líquido iónico que contiene iones sulfonato
|
|
WO2013148748A1
(en)
|
2012-03-29 |
2013-10-03 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
ES2694787T3
(es)
|
2013-02-21 |
2018-12-27 |
Pfizer Inc. |
Formas sólidas de un inhibidor selectivo de CDK4/6
|
|
CN108434149B
(zh)
|
2013-03-15 |
2021-05-28 |
G1治疗公司 |
针对Rb阳性异常细胞增殖的HSPC节制性治疗
|
|
WO2014144740A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
EA032094B1
(ru)
*
|
2013-03-15 |
2019-04-30 |
Консерт Фармасьютикалс, Инк. |
Дейтерированный палбоциклиб
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
US9717735B2
(en)
|
2014-04-17 |
2017-08-01 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
|
WO2016015598A1
(en)
*
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
|
EP3174878A4
(en)
*
|
2014-07-31 |
2017-12-27 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
|
US20170240543A1
(en)
*
|
2014-08-14 |
2017-08-24 |
Sun Pharmaceutical Industries Limited |
Crystalline forms of palbociclib
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
|
CN105616419A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
|
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
US20170306046A1
(en)
|
2014-11-12 |
2017-10-26 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
|
AU2016214897B9
(en)
*
|
2015-02-03 |
2020-06-04 |
Jiangsu Hengrui Medicine Co., Ltd. |
Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
|
CN104910149A
(zh)
*
|
2015-04-28 |
2015-09-16 |
上海百奇医药科技有限公司 |
一种Palbociclib制备方法
|
|
CN106117199A
(zh)
*
|
2015-05-04 |
2016-11-16 |
江苏恒瑞医药股份有限公司 |
一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
|
|
PT3305785T
(pt)
*
|
2015-05-29 |
2021-10-13 |
Teijin Pharma Ltd |
Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável
|
|
HUE047477T2
(hu)
|
2015-06-04 |
2020-04-28 |
Pfizer |
Palbociclib szilárd dózisformái
|
|
CN106317053A
(zh)
*
|
2015-06-29 |
2017-01-11 |
北大方正集团有限公司 |
一种帕博昔布晶型a的制备方法
|
|
WO2017021111A1
(en)
*
|
2015-08-05 |
2017-02-09 |
Ratiopharm Gmbh |
New crystalline form and acetic acid adducts of palbociclib
|
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
CN106474129A
(zh)
*
|
2015-09-01 |
2017-03-08 |
上海方楠生物科技有限公司 |
一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
|
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
|
CN108463248B
(zh)
|
2015-11-12 |
2022-10-21 |
西雅图基因公司 |
聚糖相互作用化合物及使用方法
|
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
|
CN106800554A
(zh)
*
|
2015-11-26 |
2017-06-06 |
上海科胜药物研发有限公司 |
一种帕博西尼二盐酸盐的晶型及其制备方法
|
|
CN106800553A
(zh)
*
|
2015-11-26 |
2017-06-06 |
上海科胜药物研发有限公司 |
一种帕博西尼二羟乙基磺酸盐的晶型
|
|
CN105541832A
(zh)
*
|
2015-12-15 |
2016-05-04 |
南京艾德凯腾生物医药有限责任公司 |
一种羟乙基磺酸盐帕布昔利布的制备方法
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
CN107137408A
(zh)
*
|
2016-03-01 |
2017-09-08 |
江苏恒瑞医药股份有限公司 |
一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
|
|
CN107137409A
(zh)
*
|
2016-03-01 |
2017-09-08 |
江苏恒瑞医药股份有限公司 |
一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
US10690673B2
(en)
|
2016-03-29 |
2020-06-23 |
Mayo Foundation For Medical Education And Research |
Method of treating cancer metastasis by CDK 4/6 inhibitors
|
|
WO2018001270A1
(en)
*
|
2016-06-30 |
2018-01-04 |
Noratech Pharmaceuticals, Inc. |
Palbociclib prodrugs and composition thereof
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
JP6870082B2
(ja)
*
|
2016-07-07 |
2021-05-12 |
プランテックス・リミテッド |
二メシル酸パルボシクリブの固体形態
|
|
MA45920B1
(fr)
|
2016-08-15 |
2021-08-31 |
Pfizer |
Inhibiteurs de pyridopyrimidinone cdk2/4/6
|
|
WO2018065999A1
(en)
|
2016-10-07 |
2018-04-12 |
Mylan Laboratories Limited |
Novel polymorph of an intermediate for palbociclib synthesis
|
|
ES2934846T3
(es)
|
2016-10-20 |
2023-02-27 |
Pfizer |
Inhibidores de CDK para tratamiento de PAH
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
WO2018091999A1
(en)
|
2016-11-16 |
2018-05-24 |
Pfizer Inc. |
Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
PT3546456T
(pt)
*
|
2016-11-28 |
2022-02-28 |
Teijin Pharma Ltd |
Cristal de derivado da pirido[3,4-d]pirimidina ou seu solvato
|
|
IL267795B2
(en)
|
2017-01-06 |
2023-02-01 |
G1 Therapeutics Inc |
Combination therapy for the treatment of cancer
|
|
CA3054939A1
(en)
|
2017-03-03 |
2018-09-07 |
Seattle Genetics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN110573183A
(zh)
*
|
2017-04-21 |
2019-12-13 |
上海方楠生物科技有限公司 |
一种帕博西林组合物及其制备方法
|
|
EA201992768A1
(ru)
|
2017-06-29 |
2020-05-19 |
Г1 Терапьютикс, Инк. |
Морфологические формы g1t38 и способы их получения
|
|
EA202090402A1
(ru)
|
2017-07-28 |
2020-05-19 |
Синтон Б.В. |
Фармацевтическая композиция, содержащая пальбоциклиб
|
|
CA3088381A1
(en)
*
|
2018-01-29 |
2019-08-01 |
Beta Pharma, Inc. |
2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
|
|
US11759450B2
(en)
|
2018-02-06 |
2023-09-19 |
The Board Of Trustees Of The University Of Illinois |
Substituted benzothiophene analogs as selective estrogen receptor degraders
|
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
|
|
US11911383B2
(en)
|
2018-05-14 |
2024-02-27 |
Pfizer Inc. |
Oral solution formulation
|
|
EP3826622A1
(en)
|
2018-07-23 |
2021-06-02 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with pi3k inhibitor, gdc-0077
|
|
KR20210049847A
(ko)
|
2018-08-24 |
2021-05-06 |
쥐원 쎄라퓨틱스, 인크. |
1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
|
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
|
|
EP3863618A1
(en)
|
2018-10-08 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with pi3k alpha inhibitors and metformin
|
|
US11424484B2
(en)
|
2019-01-24 |
2022-08-23 |
Octet Scientific, Inc. |
Zinc battery electrolyte additive
|
|
US20220125777A1
(en)
|
2019-02-01 |
2022-04-28 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
JP2022533833A
(ja)
|
2019-05-24 |
2022-07-26 |
ファイザー・インク |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
|
BR112022003490A2
(pt)
|
2019-08-26 |
2022-05-24 |
Arvinas Operations Inc |
Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida
|
|
JP2023504436A
(ja)
|
2019-12-03 |
2023-02-03 |
ジェネンテック， インコーポレイテッド |
乳がんの治療のための併用療法
|
|
TW202146017A
(zh)
|
2020-03-05 |
2021-12-16 |
美商輝瑞股份有限公司 |
間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN116113407A
(zh)
|
2020-07-15 |
2023-05-12 |
辉瑞公司 |
用于癌症治疗的kat6抑制剂方法及组合
|
|
CA3189632A1
(en)
|
2020-07-20 |
2022-01-27 |
Pfizer Inc. |
Combination therapy
|
|
WO2022063119A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN113845520A
(zh)
*
|
2021-09-09 |
2021-12-28 |
安徽皓元药业有限公司 |
一种帕布昔利布乳清酸盐及其制备方法
|
|
US20240398832A1
(en)
|
2021-12-10 |
2024-12-05 |
Eli Lilly And Company |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
|
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
CN114195784A
(zh)
*
|
2021-12-29 |
2022-03-18 |
斯坦德标准技术研究(湖北)有限公司 |
帕博西尼有关物质及其制备方法和应用
|
|
EP4302755B1
(en)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
|
US20260027087A1
(en)
|
2022-07-29 |
2026-01-29 |
Pfizer Inc. |
Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
|
|
TW202539669A
(zh)
|
2022-08-31 |
2025-10-16 |
美商亞文納營運公司 |
雌激素受體降解劑之給藥方案
|
|
TWI863667B
(zh)
|
2022-11-02 |
2024-11-21 |
美商佩特拉製藥公司 |
用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
|
WO2024201334A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
|
|
TW202532065A
(zh)
|
2023-12-04 |
2025-08-16 |
美商建南德克公司 |
治療乳癌之組合療法
|
|
WO2025202854A1
(en)
|
2024-03-27 |
2025-10-02 |
Pfizer Inc. |
Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
|
|
WO2026025013A2
(en)
|
2024-07-26 |
2026-01-29 |
Pfizer Inc. |
Combination therapy using cdk4 inhibitors for cancer treatments
|